A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
Status:
Recruiting
Trial end date:
2023-09-15
Target enrollment:
Participant gender:
Summary
This is a first-in-human, multi-center clinical study to determine the safety, Maximum
Tolerated Dose (MTD) and/or Optimal Biological Dose (OBD) as well as the optimal schedule for
intravenous (IV) and/or subcutaneous (SC) administrations of RO7293583 with or without
obinutuzumab pretreatment, in participants with unresectable metastatic TYRP1-positive
melanomas who have progressed on standard of care (SOC) treatment, are intolerant to SOC, or
are non-amenable to SOC. This study will include an initial single participant
dose-escalation part one followed by a multiple participant dose-escalation part two with the
possibility of expansion.